A new vaccine, called NDV-HXP-S, is the first in clinical trials to use a new molecular design that is widely expected to create more potent antibodies
The world needs more affordable and accessible COVID-19 vaccines. A new formula made in chicken eggs may be an answer.
Lab technicians working on egg-based vaccines at the Institute of Vaccines and Medical Biologicals (IVAC) in Vietnam. Photo: PATH/Matthew Dakin.
During the 2009 influenza A/H1N1 pandemic, PATH began preparing for the next global outbreak. PATH partnered with vaccine manufacturers in low- and middle-income countries to increase egg-based flu vaccine production capacity.
The next “big one” turned out to be the coronavirus pandemic. Scientists have developed a handful of safe, effective vaccines against COVID-19 at unprecedented speeds, but demand is seriously outpacing supply and distribution is far from equitable.
COVID-19 vaccines minus the needle?
By Thomas Curwen - Los Angeles Times
LOS ANGELES With 13 COVID-19 vaccines in use around the world, pharmaceutical companies are exploring second-generation technology that could change how doses are administered and distributed.
These vaccines could be taken orally as a capsule that could be swallowed, as a tablet that dissolves under the tongue or as a nasal spray. Such formulations would not require refrigeration, nor would they need health care workers to administer them.
The efforts are in early stages with no guarantee of success. Research and development costs are steep, and only a small number of companies none with a vaccine currently authorized for use are exploring these alternate methods. The work may seem like a gamble but could play a critical role in ending the pandemic.
Print
With 13 COVID-19 vaccines in use around the world, pharmaceutical companies are exploring second-generation technology that could change how doses are administered and distributed.
These vaccines could be taken orally as a capsule that could be swallowed, as a tablet that dissolves under the tongue or as a nasal spray. Such formulations would not require refrigeration, nor would they need healthcare workers to administer them.
The efforts are in early stages with no guarantee of success. Research and development costs are steep, and only a small number of companies none with a vaccine currently authorized for use are exploring these alternate methods. The work may seem like a gamble but could play a critical role in ending the pandemic.